Acne Vulgaris Therapeutics - Pipeline Analysis, Clinical Trials & Results, Patents, Designations, Collaborations, Patient Size, Epidemiology Forecast to 2023, and Unmet Needs within the Market

Overview

Acne vulgaris develops on the face and upper trunk and most often affects adolescents. The causes of the acne include excess oil production, clogging of air follicles by oil and dead skin cells, and excess activity of androgens. The clinical presentation of acne vulgaris ranges from a mild comedonal form to severe inflammatory cystic acne of the face, chest, and back.

ACNE VULGARIS THERAPEUTICS DRUG CANDIDATES UNDER DEVELOPMENT (2017)

According to the American Academy of Dermatology (AAD), acne vulgaris has a prevalence of over 90% in the population between 10 to 20 years, and a point-prevalence of approximately 85% in the population between 15 to 24 years, globally. In 2016, in the U.S., the cost of acne vulgaris was above $3 billion per year in terms of treatment and loss of productivity. Sol-Gel Technologies Ltd. is in the process of research and development of three products for the treatment of acne vulgaris. PR023 is in early stages of development by the Realm Therapeutics, Inc. for the treatment of acne vulgaris. Increased early stage drug candidates and positive clinical trial results of the drugs being developed by the different pharmaceutical companies, are the major drivers for the acne vulgaris pipeline.

Pipeline Analysis

As of November 2017, the acne vulgaris therapeutics pipeline comprises of 49 drug candidates in different stages of development.

Epidemiology Forecast

Acne vulgaris epidemiology analysis forecasts an increase in the total number of prevalent cases in population aged between 10 to 45 years in the 7MM, from 166 million cases in 2016 to 178 million cases in 2023.

ACNE VULGARIS THERAPEUTICS TREATMENT USAGE PATTERN IN 7MM (2016-2023)

Competitive Landscape

Some of the players developing drugs for the treatment of acne vulgaris include Sol-Gel Technologies Ltd., Realm Therapeutics, Inc., Sienna Biopharmaceuticals, Inc., and Promius Pharma, LLC (subsidiary of Dr. Reddy’s Laboratories Ltd.).